242 related articles for article (PubMed ID: 26389739)
1. Structure-based energetics of protein interfaces guides foot-and-mouth disease virus vaccine design.
Kotecha A; Seago J; Scott K; Burman A; Loureiro S; Ren J; Porta C; Ginn HM; Jackson T; Perez-Martin E; Siebert CA; Paul G; Huiskonen JT; Jones IM; Esnouf RM; Fry EE; Maree FF; Charleston B; Stuart DI
Nat Struct Mol Biol; 2015 Oct; 22(10):788-94. PubMed ID: 26389739
[TBL] [Abstract][Full Text] [Related]
2. A Heat-Induced Mutation on VP1 of Foot-and-Mouth Disease Virus Serotype O Enhanced Capsid Stability and Immunogenicity.
Dong H; Lu Y; Zhang Y; Mu S; Wang N; Du P; Zhi X; Wen X; Wang X; Sun S; Zhang Y; Guo H
J Virol; 2021 Jul; 95(16):e0017721. PubMed ID: 34011545
[TBL] [Abstract][Full Text] [Related]
3. Chimeric O1K foot-and-mouth disease virus with SAT2 outer capsid as an FMD vaccine candidate.
Kotecha A; Perez-Martin E; Harvey Y; Zhang F; Ilca SL; Fry EE; Jackson B; Maree F; Scott K; Hecksel CW; Harmsen MM; Mioulet V; Wood B; Juleff N; Stuart DI; Charleston B; Seago J
Sci Rep; 2018 Sep; 8(1):13654. PubMed ID: 30209254
[TBL] [Abstract][Full Text] [Related]
4. Structures of Foot-and-Mouth Disease Virus with Bovine Neutralizing Antibodies Reveal the Determinant of Intraserotype Cross-Neutralization.
He Y; Li K; Wang L; Sun Z; Cao Y; Li P; Sun P; Bao H; Zhou S; Wang S; Bai X; Liu X; Zhao L; Fan X; Liu Z; Lu Z; Yang C; Lou Z
J Virol; 2021 Nov; 95(24):e0130821. PubMed ID: 34586859
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protective efficacy of a novel foot-and-mouth disease virus empty-capsid-like particle with improved acid stability.
Xie Y; Li H; Qi X; Ma Y; Yang B; Zhang S; Chang H; Yin X; Li Z
Vaccine; 2019 Mar; 37(14):2016-2025. PubMed ID: 30808570
[TBL] [Abstract][Full Text] [Related]
6. Mutation in the VP2 gene of P1-2A capsid protein increases the thermostability of virus-like particles of foot-and-mouth disease virus serotype O.
Ganji VK; Biswal JK; Lalzampuia H; Basagoudanavar SH; Saravanan P; Tamil Selvan RP; Umapathi V; Reddy GR; Sanyal A; Dechamma HJ
Appl Microbiol Biotechnol; 2018 Oct; 102(20):8883-8893. PubMed ID: 30136205
[TBL] [Abstract][Full Text] [Related]
7. Custom-engineered chimeric foot-and-mouth disease vaccine elicits protective immune responses in pigs.
Blignaut B; Visser N; Theron J; Rieder E; Maree FF
J Gen Virol; 2011 Apr; 92(Pt 4):849-59. PubMed ID: 21177923
[TBL] [Abstract][Full Text] [Related]
8. A Prime-Boost Vaccination Strategy in Cattle to Prevent Foot-and-Mouth Disease Using a "Single-Cycle" Alphavirus Vector and Empty Capsid Particles.
Gullberg M; Lohse L; Bøtner A; McInerney GM; Burman A; Jackson T; Polacek C; Belsham GJ
PLoS One; 2016; 11(6):e0157435. PubMed ID: 27294397
[TBL] [Abstract][Full Text] [Related]
9. Intra-serotype SAT2 chimeric foot-and-mouth disease vaccine protects cattle against FMDV challenge.
Maree FF; Nsamba P; Mutowembwa P; Rotherham LS; Esterhuysen J; Scott K
Vaccine; 2015 Jun; 33(25):2909-16. PubMed ID: 25930116
[TBL] [Abstract][Full Text] [Related]
10. Application of the thermofluor PaSTRy technique for improving foot-and-mouth disease virus vaccine formulation.
Kotecha A; Zhang F; Juleff N; Jackson T; Perez E; Stuart D; Fry E; Charleston B; Seago J
J Gen Virol; 2016 Jul; 97(7):1557-1565. PubMed ID: 27002540
[TBL] [Abstract][Full Text] [Related]
11. Rapid Engineering of Foot-and-Mouth Disease Vaccine and Challenge Viruses.
Lee SY; Lee YJ; Kim RH; Park JN; Park ME; Ko MK; Choi JH; Chu JQ; Lee KN; Kim SM; Tark D; Lee HS; Ko YJ; Seo MG; Park JW; Kim B; Lee MH; Lee JS; Park JH
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566375
[TBL] [Abstract][Full Text] [Related]
12. Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs.
Du Y; Dai J; Li Y; Li C; Qi J; Duan S; Jiang P
Vet Immunol Immunopathol; 2008 Aug; 124(3-4):274-83. PubMed ID: 18511133
[TBL] [Abstract][Full Text] [Related]
13. Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice.
Ren ZJ; Tian CJ; Zhu QS; Zhao MY; Xin AG; Nie WX; Ling SR; Zhu MW; Wu JY; Lan HY; Cao YC; Bi YZ
Vaccine; 2008 Mar; 26(11):1471-81. PubMed ID: 18289743
[TBL] [Abstract][Full Text] [Related]
14. Correlation between efficacy and structure of recombinant epitope vaccines against bovine type O foot and mouth disease virus.
Fang M; Li J; Wang H; Yang M; Zhang Y; Zhou L; Wei H; Yang G; Yu Y; Wei X; Yu Y; Wang L; Wan M
Biotechnol Lett; 2012 May; 34(5):839-47. PubMed ID: 22286179
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Porcine Parvovirus VP2 Virus-like Particles with Epitopes of South African Serotype 2 Foot-and-Mouth Disease Virus Elicits Specific Humoral and Cellular Responses in Mice.
Li Q; Ma X; Shen Y; Dai J; Nian X; Shang X; Chen J; Wubshet AK; Zhang J; Zheng H
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675963
[TBL] [Abstract][Full Text] [Related]
16. Characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and application in identification of antigenic variation in relation to vaccine strain selection.
Yang M; Xu W; Goolia M; Zhang Z
Virol J; 2014 Aug; 11():136. PubMed ID: 25085313
[TBL] [Abstract][Full Text] [Related]
17. Implication of Broadly Neutralizing Bovine Monoclonal Antibodies in the Development of an Enzyme-Linked Immunosorbent Assay for Detecting Neutralizing Antibodies against Foot-and-Mouth Disease Virus Serotype O.
Cao Y; Li K; Wang S; Fu Y; Sun P; Li P; Bai X; Zhang J; Ma X; Xing X; Zhou S; Bao H; Li D; Chen Y; Li Z; Lu Z; Liu Z
J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31578261
[TBL] [Abstract][Full Text] [Related]
18. The pH Stability of Foot-and-Mouth Disease Virus Particles Is Modulated by Residues Located at the Pentameric Interface and in the N Terminus of VP1.
Caridi F; Vázquez-Calvo A; Sobrino F; Martín-Acebes MA
J Virol; 2015 May; 89(10):5633-42. PubMed ID: 25762735
[TBL] [Abstract][Full Text] [Related]
19. Preserved immunogenicity of an inactivated vaccine based on foot-and-mouth disease virus particles with improved stability.
Caridi F; Vázquez-Calvo Á; Borrego B; McCullough K; Summerfield A; Sobrino F; Martín-Acebes MA
Vet Microbiol; 2017 May; 203():275-279. PubMed ID: 28619156
[TBL] [Abstract][Full Text] [Related]
20. Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen.
Porta C; Kotecha A; Burman A; Jackson T; Ren J; Loureiro S; Jones IM; Fry EE; Stuart DI; Charleston B
PLoS Pathog; 2013 Mar; 9(3):e1003255. PubMed ID: 23544011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
